AI-driven blood test for early cancer detection.
Public company, workplace, funding, and market signals
Updated Jul 28, 2026
PIPE / private placement as part of business combination
Dec 2025 · Perceptive Advisors and RA Capital
Feb 2024 · Roche
Dec 2021 · Perceptive Advisors and RA Capital Management
Aug 2020 · Bain Capital Life Sciences and Perceptive Advisors
Jul 2019 · RA Capital Management and Polaris Partners
Mar 2017 · Andreessen Horowitz
Jun 2016 · Andreessen Horowitz
Investors
Freenome · Jul 2026
Closing of the business combination with Perceptive Capital Solutions Corp and debut as a public company on Nasdaq under ticker FRNM.
Freenome · Nov 2025
Expanded international partnership with Roche to commercialize Freenome’s cancer screening technology outside the U.S. and deepen R&D collaboration.
Freenome · Aug 2025
Strategic U.S. commercialization deal for Freenome’s CRC blood test, with upfront cash, milestones, R&D funding, and an equity investment.
Freenome · Feb 2024
Large financing led by Roche to accelerate Freenome’s early cancer detection platform and pipeline.
Freenome · Dec 2021
Major growth financing led by Perceptive Advisors and RA Capital to advance PREEMPT CRC and the broader multiomics platform.